Eli Lilly's weight loss pill will likely be the market-leading product, says BofA's Tim Anderson
Eli Lily shares. Let's have a look at those after that news that we just uh reported that the pharma giant released more data on its obesity pill. Patients with obesity and diabetes lost about 10.5% of their body weight.The data clears the way for Lily to seek regulatory approval. Shares are up 1.7% when they got some data on this a month or so ago or just under a month ago they did fall. Let's get clarity on which bit of the data outweighs the other.Tim Anderson, Bank of America Security senior pharma anal ...